Participants

Steering Committee


Sarah CHAN, BSc(Hons), LLB, MA(Health Care Ethics and Law)

Chancellor’s Fellow, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh

Sarah Chan is a Chancellor’s Fellow at the Usher Institute for Populations Health Sciences and Informatics, University of Edinburgh. Her current research interests include the ethics of new biotechnologies and their impact on humans and our concept of humanity: in particular, genetic mcesarianipulation, enhancement and interspecies technology. Prior to this, she conducted work on the EU-CLEMIT project involving the ethics of “creating and redesigning human beings,” including ethics in gene and cell therapy, artificial and assisted reproductive technologies, genetic modification and enhancement; the ethics of stem cell research; and regulation of new technologies and public policy. She has previously worked on regulation of embryo and stem cell research in Australia and public attitudes and education regarding gene technology. She conducted laboratory-based research in molecular biology examining the genetics of male reproduction, and trained as a lawyer specialising in legal theory, health care law and scientific regulation.


Peter J DONOVAN, PhD

Professor of Developmental and Cell Biology and of Biological Chemistry Co-Director, Sue and Bill Gross Stem Cell Center, University of California, Irvine

Peter J Donovan, PhD, is Professor of Developmental and Cell Biology and of Biological Chemistry at the University of California, Irvine and Co-Director of the Sue and Bill Gross Stem Cell Research Center. Dr Donovan’s laboratory studies the molecular mechanisms regulating primordial germ cell development in mice as well as the mechanism regulating the meiotic cell cycle in mammals. His laboratory pioneered the development of pluripotent stem cells from primordial germ cells in mice and, with John Gearhart, developed the same cell type from human germ cells. His research interests center around the mechanisms regulating developmental potency in germ cells and stem cells. His laboratory was one of the first to receive NIH funding to study human embryonic stem (ES) cells and he serves on one of only two NIH study sections that reviews proposed studies on human ES cells. He serves as a member of the board of reviewing editors of Science.


Tom DouglasTom DOUGLAS, MD, DPhil

Wellcome Trust Postdoctoral Research Fellow, Oxford Uehiro Centre for Practical Ethics, Brasenose College

Tom Douglas is a Senior Research Fellow in the Oxford Uehiro Centre for Practical Ethics and a Golding Junior Fellow at Brasenose College. He is also Principal Investigator on the Wellcome Trust-funded project ‘Neurointerventions in Crime Prevention: An Ethical Analysis’. He initially qualified as a medical doctor at the University of Otago (New Zealand) before taking up a Rhodes Scholarship in Oxford, where he received his BA in Philosophy, Politics & Economics in 2005, and his DPhil in Philosophy in 2010. From 2010-2013 he was a Wellcome Trust Research Fellow in the Uehiro Centre and a Junior Research Fellow at Balliol College.  Tom’s research lies mainly in practical and normative ethics. In practical ethics, his work focuses on the ethics of using medical technologies for ‘non-medical’ purposes, such as crime prevention and behaviour change. In normative ethics he is primarily interested in the nature of moral improvement and in tensions between special obligations and requirements of fairness. Previously, he has written on slippery slope arguments, organ donation policy, the philosophical foundations of injury compensation law, and the dual-use dilemma.


gyngellChris GYNGELL

Research Fellow in Neuroethics, OCN & OLLRP, University of Oxford

Chris Gyngell is a Marie Skłodowska-Curie Fellow with the Uehiro Centre for Practical Ethics at Oxford University.  His research interests lie primarily in bioethics, the philosophy of psychiatry, and moral theory.  He is currently overseeing a research project titled “‘Selecting, Creating and Modifying Embryos”, which will investigate the ethical, political and legal implications of new reproductive technologies, such as the gene editing technique CRISPR. This project will be funded by the Marie Skłodowska-Curie Fellowships programme.


John HARRIS, FMedSci, BA, DPhil

Lord Alliance Professor of Bioethics, Director of Institute for Science, Ethics and Innovation, School of Law, University of Manchester; Visiting Professor, Department of Philosophy, Logic and Scientific Method, London School of Economics and Political Science

John Harris is the Lord Alliance Professor of Bioethics, Director of the Institute for Science, Ethics and Innovation (iSEI), School of Law, University of Manchester and is joint Editor-in-Chief of The Journal of Medical Ethics, the highest ranked journal globally in Medical Ethics. He was elected a Fellow of the United Kingdom Academy of Medical Sciences (FMedSci) in 2001, is a Fellow of The Hastings Center and has been a member of The United Kingdom Human Genetics Commission since its foundation in 1999, and many other advisory commissions. Recent Books Include: Clones Genes and Immortality, Oxford University Press, 1998, John Harris, Ed; Bioethics, Oxford Readings in Philosophy Series, Oxford University Press, 2001, Justine C Burley and John Harris, Eds; A Companion To Genethics: Philosophy and the genetic revolution, Basil Blackwell, Oxford, 2002 (Blackwell’s Companions to Philosophy series); On Cloning, Routledge. London, 2004; and, Enhancing Evolution: The Ethical Case for Making Better People, Princeton University Press, 2007.


lovell-badgeRobin LOVELL-BADGE, PhD

Group Leader, Laboratory of Stem Cell Biology and Developmental Genetics, The Francis Crick Institute

Robin Lovell-Badge obtained his BSc in Zoology at University College, London in 1975. He obtained his PhD in Embryology at University College London in 1978, carrying out mouse stem cell and embryo research with Martin Evans. After postdoctoral research in Cambridge, also with Martin Evans, and then in Paris, he established his independent laboratory in 1982 at the MRC Mammalian Development Unit, University College, London, directed by Anne McLaren. He has had long-standing interests in the biology of stem cells, in how genes work in the context of embryo development, and how decisions of cell fate are made. Major themes of his current work include sex determination, development of the nervous system and pituitary, and the biology of stem cells within the early embryo, the CNS and the pituitary. He is also very active in both public engagement and policy work, notably around stem cells, genetics, human embryo and animal research, and in ways science is regulated and disseminated. He was elected a member of EMBO in 1993, a Fellow of the Academy of Medical Sciences in 1999, and a fellow of the Royal Society in 2001. He has received the Louis Jeantet Prize for Medicine (1995), the Amory Prize (Awarded by the American Academy of Arts and Sciences) (1996), the Feldberg Foundation Prize (2008), and the Waddington Medal of the British Society for Developmental Biology (2010). He is also a Distinguished Visiting Professor at the University of Hong Kong (2009-2015) and the President of the Institute of Animal Technologists.


Debra JH MATHEWS, PhD, MA

Assistant Director for Science Programs, Johns Hopkins Berman Institute of Bioethics Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine

Debra JH Mathews, Ph.D., M.A., is the Assistant Director for Science Programs for the Berman Institute of Bioethics at Johns Hopkins University. Dr. Mathews earned her B.S. in Biology from the Pennsylvania State University and a Ph.D. in genetics from Case Western Reserve University. Concurrent with her Ph.D., she earned a master’s degree in bioethics from Case. She completed a post-doctoral fellowship in genetics at Johns Hopkins, where she continued her work on human genetic variation and human population history. She also completed the Greenwall Fellowship in Bioethics and Health Policy, which is jointly administered by Johns Hopkins and Georgetown universities. As a Greenwall Fellow, Dr. Mathews worked at the Genetics and Public Policy Center, researching the views of geneticists on their role(s) in science policy formation and public engagement. In addition, during a three-month internship at the Department of Health and Human Services in the Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, she worked with the Privacy Advocate on issues related to large data systems. As the Assistant Director for Science Programs, Dr. Mathews is responsible for overseeing the Stem Cell Policy and Ethics program (SCoPE) and the Program in Ethics and Brain Sciences, as well as other bench research-related endeavors in the Berman Institute. Her research interests focus on the intersection of science, public policy and society.


regenbergAlan REGENBERG, MBe

Director of Outreach and Research Support, Johns Hopkins Berman Institute of Bioethics

 Alan Regenberg, MBe is the Director of Outreach and Research Support at the Johns Hopkins Berman Institute of Bioethics. His team is responsible for broad dissemination and active public engagement around the Institute’s diverse portfolio of scholarship. This includes rapid-response research in addition to managing/curating the institute’s internet-based assets and successful, social media-based, public-engagement efforts, such as: The Berman Institute Bioethics Bulletin BlogFacebook page, Twitter feed, YouTube Channel, and Weekly Bioethics Email Digests. Alan and his team also support a broad range of research projects and programs, including the Berman Institute’s science programs: the Stem Cell Policy and Ethics (SCOPE) Program; the Program in Ethics and Brain Sciences (PEBS-Neuroethics); and the Hinxton Group, an international consortium on stem cells, ethics and law. Alan’s research interests are diverse, and have most recently focused on bioethics and social media, global bioethics, stem cell science and neuroethics. Alan received his Master of Bioethics degree from the University of Pennsylvania, and his undergraduate degree in History and Psychology from Rutgers University.  On Twitter @aregenberg.


Participants


benvenistyNissim BENVENISTY, MD, PhD

Professor of Genetics, The Herbert Cohn Chair in Cancer Research, Director, The Azrieli Center for Stem Cells and Genetic Research, Institute of Life Sciences, The Hebrew University of Jerusalem

Prof. Nissim Benvenisty is the Herbert Cohn Chair in Cancer Research and the director of The Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. He earned his M.D. and Ph.D. degrees from the Hebrew University, and conducted postdoctoral studies at Harvard University. Prof. Benvenisty’s research projects focus on stem cell biology, tissue engineering, human genetics, and cancer research. He published numerous original and review papers on human pluripotent stem cells, and serves on the editorial board of various stem cell related journals. He is a member of the steering committee of the International Stem Cell Initiative, and the Board of Directors of the International Society for Stem Cell Research (ISSCR). Prof. Benvenisty presents the issue of human embryonic stem cells in many international conferences, and gave testimonies before the US Senate and the European Union. He was awarded several prizes among them the Foulkes Prize (London), the Hestrin Prize, the Teva Prize, and the Kaye Prize.


Elizabeth BOHM

Senior Policy Adviser, The Royal Society

Following degrees in both biology and law, Elizabeth became a qualified lawyer and worked in a full service law firm before transitioning into policy work. She specialises in the areas where law and science cross over with expertise in research ethics and regulation. Since arriving in the UK she worked for the British Medical Association and Wellcome Trust before joining the Royal  Society. Currently she manages a portfolio of projects that encompass ethical conduct of research, public participation in policy making and new and emerging technologies (these include synthetic biology, gain of function, GM, environmental observation and biological and toxin weapons).


Abredenoordnnelien BREDENOORD, PhD

Associate Professor of Biomedical Ethics, University Medical Center, Utrecht

Annelien Bredenoord (1979) is an associate professor of biomedical ethics at UMC Utrecht as well as member of the Dutch Senate (First Chamber) on behalf of Democrats ’66. She is member of the Ethics & Public Policy Commitee of the ISSCR.She examines the ethical issues raised by translational medicine, particularly the rapid developments in regenerative medicine, stem cell research, genetics/genomics and biobanking. She teaches ethics at the Medical School and is supervisor of several PhD students, among which in a ZonMw funded project on the ethics of pediatric biobanks and a BioMedical Materials Program (BMM) funded project on the ethics of novel regenerative technology. She obtained a VENI-grant to study the ethics of pluripotent stem cell research (“Ethics of translational stem cell research: moving pluripotent stem cells to the clinic”). She is member of several (inter)national committees among which the Young Academy of the Royal Netherlands Academy of Arts and Sciences (Jonge Akademie, KNAW), the Young Health Council of the Netherlands (Jonge Gezondheidsraad), the Ethics Committee of the Dutch Association for Clinical Genetics, UMC Utrecht’s Research Ethics Committee (METC), National Indication Committee Preimplantation Genetic Diagnosis and the International Stem Cell Forum Ethics Working Party.


buckleRobin BUCKLE, MD

Director of Science Programs, Medical Research Council, London, UK

Dr. Rob Buckle is Director of Science Programmes at the MRC, with responsibility for the four MRC Research Boards that allocate and oversee the majority of MRC’s research funding. The four Boards distribute an annual budget of £170M in support of University and NHS-based research.  Within this role Rob has responsibility for two distinct areas of MRC’s work, in regenerative medicine and neurodegeneration research. For the former, Rob is Director of the UK Regenerative Medicine Platform, a £25M managed programme established by three UK research councils (MRC, EPSRC and BBSRC) to deliver translational research that will drive new therapeutic approaches in regenerative medicine. The UKRMP is central to the UK’s overall strategic approach in this area, and provides critical linkage between the discovery science base and efforts to apply this burgeoning knowledge for both patient and commercial benefit. In relation to neurodegeneration research, Rob oversees MRC’s strategic activities in this area, where for example he is a member of the MRC Dementias Platform UK Oversight Board and, at the international level, the Executive Groups for both the EU Joint Programming Initiative in Neurodegeneration (JPND) and Centres of Excellence in Neurodegeneration (COEN) initiatives.


cesariFrancesca, CESARI, PhD

Chief Biological Science Editor, Nature

Francesca Cesari is Chief Biological Sciences Editor at Nature, overseeing editorial content and management of the biological science section of Nature.  She has a Master with honours in Molecular Biology from University of Rome “La Sapienza”, Italy, and obtained her Ph.D. from the Institute of Cell Biology in Tübingen, Germany, where she also began her post-doctoral work. She completed her post-doctoral work at The Wellcome Trust/Cancer Research Gurdon Institute in Cambridge, UK. Prior to joining Nature she was a Senior Editor of Nature Reviews Molecular Biology and briefly worked at Nature Cell Biology as a Senior Editor. She was the Stem Cell and Development Editor at Nature for some years before her appointment to Chief Biological Sciences Editor in 2014.


clarkAmander CLARK, PhD

Professor and Vice Chair of the Department of Molecular, Cell and Developmental Biology in the Life Sciences, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles

Amander Clark PhD is Professor and Vice Chair of the Department of Molecular Cell and Developmental Biology, Director of the Embryonic Stem Cell Derivation laboratory and Key member of the Eli and Edythe Broad Center of Regenerative and Stem Cell Research at the University of California Los Angeles. Dr Clark’s work is focused on the use of pluripotent stem cells to understand the cell and molecular basis of human reproduction and embryo development, with a focus on germline epigenetic reprogramming. Dr Clark’s laboratory is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Concern Foundation and the Alternatives Research and Development Foundation.  Dr Clark is a recipient of a Young Investigator Award from the Lance Armstrong Foundation, a Research and Career Development award from STOP Cancer, and a Young Investigator Award from the International Society for Stem Cell Research.


colville-nashPaul COLVILLE-NASH, PhD

Programme Manager, Molecular and Cellular Medicine Board, UK Medical Research Council

Paul Colville-Nash is a programme manager at the UK Medical Research Council (MRC), managing delivery of the Council’s research programmes in developmental biology, stem cell research and regenerative medicine. He provides the lead for the MRC’s Regenerative Medicine Research Committee, the Secretariat for the Steering Committee for the UK Stem Cell Bank and Use of Human Stem Cells, and sits as a UK representative on the International Stem Cell Forum. Prior to joining MRC, Paul worked as a research scientist in academia, in a contract research organisation with several major pharma and in the UK National Health Service, with research interests in the control of inflammatory diseases. He retains interests in the ethics of in vivo research within MRC and externally, sitting as an independent scientific expert on a university Animal Welfare and Ethical Review Body.


desouzaNatalie DE SOUZA, PhD

Chief Editor, Nature Methods

Natalie de Souza obtained her Ph.D. at the Rockefeller University in 2002, employing biochemical, imaging and cell culture-based approaches to study the biogenesis and traffic of oligomeric membrane proteins, in the laboratory of Sandy Simon. She then moved to developmental genetics in the laboratory of Iva Greenwald at Columbia University, where she did post-doctoral work on the regulation of LIN-12/Notch signaling in C. elegans epithelial cells, and its role in cell fate specification. She joined the journal in December 2006.


La profesora de la UDC Viviana García Llerena. / roberto lameiroViviana GARCIA LLERENA

Visiting Researcher, Institute for Science, Ethics and Innovation, School of Law, University of Manchester


greenfieldAndy GREENFIELD, MA, PhD

Program Leader, Medical Research Council, Harwell

Dr. Greenfield is a Programme Leader at the Medical Research Council’s (MRC) Mammalian Genetics Unit at Harwell. His core-funded research focuses on the identification and characterization of genes functioning in the development of the reproductive organs in the laboratory mouse and the role of equivalent human genes in disease. At the MRC, Dr. Greenfield chairs the Animal Welfare and Ethical Review Body (AWERB) that oversees the welfare of mice used in research on site. He has previously been a member of the Wellcome Trust’s Molecules, Genes and Cells Funding Panel (2003 – 2007, 2009-2010) and regularly reviews submissions to journals and funding agencies in the UK and overseas. Since 2oo9 he has been a member of the Human Fertilisation and Embryology Authority (HFEA) and now chairs its License Committee. In 2014 he chaired the 3rd scientific review of the safety and efficacy of mitochondrial replacement techniques. He is also a member of The Nuffield Council on Bioethics and was recently appointed chair of a new working group convened to explore the ethical issues raised by genome editing techniques and their potential applications.


isasiRosie ISASI, PhD, JD, MPH

Research Associate and Faculty of Medicine, McGill University

Rosario Isasi has built an international reputation as a scholar with particular expertise in the area of comparative law and ethics regarding regenerative medicine.Closely related to her academic work is her role as an ethics and policy adviser to government, professional and international bodies, such as the United Nations, where she played an active role in the adoption of the UN Declaration on Human Cloning. Most recently, she contributed to the development of harmonized ELSI and educational tools for Canadian Blood Services’ National Public Cord Blood Bank, the Centre for the Commercialization of Regenerative Medicine (CCRM) and to the Bioethics Education Project of the Royal College of Physicians and Surgeons of Canada. Rosario Isasi holds many leadership roles in major international initiatives. She is the Academic Secretary of the International Stem Cell Forum Ethics Working Party and the Ethics/Policy Adviser of the European Human Pluripotent Stem Cell Registry (hESCREG). She leads the Governance Working Group of the International Stem Cell Banking Initiative (ISCBI). Mrs. Isasi is a member of the Legal and Human Rights Advisory Board of the Genetics Policy Institute (GPI), a member of the Bioethics and Legal Advisory Board of an EC-FP7 project on Biomaterials for Tracheal Replacement in Age-related Cancer via a Humanely Engineered Airway (BIOtrachea) and on regenerative medicine legislation (RegMedLaw, Translational Centre for Regenerative Medicine, Leipzig University). Mrs. Isasi was the first post-doctoral fellow at the Canadian Program on Genomics and Global Health at Joint Centre for Bioethics, University of Toronto. She received further post-doctoral training at the Genetics and Society Project, Centre de recherche en droit public, Université de Montréal. She holds her J.D. from the Pontifical Catholic University of Peru, where she practiced corporate and health law. She received her Masters of Public Health from Boston University, USA.


liuPentao LIU, PhD

Mouse Cancer Genetics, Wellcome Trust Sanger Institute

Pentao graduated from Henan Normal University and earned his Master of Science degree from Chinese Academy of Sciences/University of Science and Technology of China. At Baylor College of Medicine, he studied molecular mechanisms of Charcoal-Marie-Tooth disease in Dr James Lupski’s laboratory. Pentao received his PhD from Baylor College of Medicine under the guidance of Professor Allan Bradley, and completed his postdoctoral training at National Cancer Institute (USA) in the laboratories of Dr Neal Copeland and Dr Nancy Jenkins. Pentao joined the Wellcome Trust Sanger Institute in September 2003. He initiated the high-throughput recombineering for the large-scale mouse mutagenesis programme at the Sanger Institute. Pentao’s laboratory is interested in transcriptional regulation in development and has been characterizing two transcription factors, Bcl11a and Bcl11b, in haematopoiesis and in breast cancer. Pentao has a particular interest in using genetic, genomic and biochemical approaches to study lineage commitment in development and also lineage maintenance once the firm commitment is achieved. Knowledge from these studies will provide a scientific basis for controllable differentiation from engineered stem cells or progenitors to functional cells, for genetic reprogramming of differentiated cells, and eventually for a better understanding of cancer initiation and progression. Pentao’s lab is also studying stem cell biology and investigating molecular mechanisms of reprogramming somatic cells to pluripotent stem cells.


dejesusMaria DE JESUS MEDINA ARELLANO

Researcher at the Legal Research Institute, National Autonomous University of Mexico

María de Jesús Medina Arellano is a full time researcher at the Legal Research Institute, National Autonomous University of Mexico (UNAM). She is also a member of the College of Bioethics, an academic civil association in Mexico focused on more liberal approaches to bioethics in the country. Her current research interests include the ethics and regulation of emerging biotechnologies and principles and human rights-based regulation for stem cell science in Mexico. During her master postgraduate studies she focused on the new paradigm of Health/Medical Law and Human Rights in Mexico. She is member of the National Research System in Mexico (CONACyT), Level I. From 2013-2014 she worked as Director of the Judiciary School of the Local Court of Nayarit.



oconnorcropDan O’CONNOR, PhD

Head of Humanities and Social Science, Wellcome Trust

Dan O’Connor is head of humanities and social science at the Wellcome Trust. He directs the trust’s funding of bioethics research and was formerly a member of faculty at the Johns Hopkins Berman Institute of Bioethics.


purnellBeverly PURNELL, PhD

Senior Editor, SCIENCE, American Association for the Advancement of Science (AAAS)

Dr. Purnell earned her Master’s and PhD in Molecular and Cell Biology from The Pennsylvania State University with projects in C. elegans sex determination and Drosophila gene expression, respectively.  She was awarded an Alexander von Humboldt fellowship to do postdoctoral work at the Max Planck Institute in Goettingen, Germany, and did research in Drosophila head development and gene regulation. She joined the AAAS and Science staff in 1997. As Senior Editor at SCIENCE Magazine, Dr. Purnell handles papers in the areas of developmental biology (including stem cells), gene regulation, reproductive biology, and related fields. Her duties include the recruitment, selection, and scientific editing of manuscripts for publication in Science. Dr. Purnell has coordinated Special Issues on topics such as Stem Cells, Reproductive Biology, Developmental Timing, Morphogenesis, Women’s Health, and Parenting.


C0092818 Sarah Rappaport

Sarah RAPPAPORT, PhD

Policy Officer, Wellcome Trust

Sarah Rappaport works in science policy at the Wellcome Trust, where the overarching goal is to ensure a good environment for research and to enhance research practice. The Policy team do this in many ways, including influencing science policy and legislation in the UK and globally, and by developing the Trust’s policies for those we fund. Sarah’s specific focus is on regulation and legislation in the UK and EU.

Before joining the Trust Sarah gained experience of both academic and clinical research: she obtained her PhD at the Behavioural Brain Sciences Centre at the University of Birmingham, and later joined the stroke research programme at St George’s Hospital, London.


schallTheodore SCHALL, MSW

Research Program Coordinator, Johns Hopkins Berman Institute of Bioethics; MBE Candidate, Department of Medical Ethics & Health Policy, University of Pennsylvania

Theo Schall is the managing editor of AJOB: Empirical Bioethics. He received his Bachelor of Liberal Arts from St. John’s College, Annapolis and Master of Social Work (Macro Practice) from the School of Social Policy and Practice, University of Pennsylvania.


schniekeAngelika SCHNIEKE, PhD

Dean of Life Sciences, Technical University of Munich

Angelika Schnieke studied bio-engineering in Hamburg and later obtained her Ph.D from the University of Edinburgh. She worked with Prof. Rudolf Jaenisch from 1978 to 1987 first at the Heinrich-Pette Institute, Hamburg and subsequently at the Whitehead Institute, Massachusetts Institute of Technology. Here she was involved in early development work on retroviral vectors, the production of transgenic animal models and gene knockouts. She subsequently joined Colorado State University where her research extended to the production of transgenic livestock species. Between 1992 and 2003 she worked with the biotechnology company PPL Therapeutics in Edinburgh as Head of Molecular Biology, later becoming Assistant Director of Research. Research work at PPL focused on the production of pharmaceutical proteins in the milk of transgenic large animals, xenotransplantation, stem cell differentiation and the development of novel technologies for the production of transgenic livestock. Some notable scientific achievements include: development of somatic cell nuclear transfer (Dolly the sheep) and the production of the first gene-targeted livestock animal. Prof. Schnieke joined the Technical University of Munich in spring 2003 to take up the Chair of Livestock Biotechnology. She became Dean of Life Sciences in October 2013.


sugarmanJeremy SUGARMAN, MD, MPH, MA

Harvey M. Meyerhoff Professor of Bioethics and Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine, Johns Hopkins Berman Institute of Bioethics

Jeremy Sugarman is an internationally recognized leader in the field of biomedical ethics with particular expertise in the application of empirical methods and evidence-based standards for the evaluation and analysis of bioethical issues. His contributions to both medical ethics and policy include his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research, global health and research oversight. Dr. Sugarman consults and speaks internationally on a range of issues related to bioethics. He has served as senior policy and research analyst for the White House Advisory Committee on Human Radiation Experiments, consultant to the National Bioethics Advisory Commission, and Senior Advisor to the Presidential Commission for the Study of Bioethical Issues. He also served on the Maryland Stem Cell Research Commission. He was the founding director of the Trent Center for Bioethics, Humanities and History of Medicine at Duke University where he was also a professor of medicine and philosophy. He is a faculty affiliate of the Kennedy Institute of Ethics at Georgetown University and an Academic Icon of the University of Malaya. Dr. Sugarman currently serves on the Scientific and Research Advisory Board for the Canadian Blood Service, the Ethics and Public Policy Committee of the International Society for Stem Cell Research, and the Board of Directors of PRIM&R (Public Responsibility in Medicine and Research). He is co-chair of the Johns Hopkins’ Institutional Stem Cell Research Oversight Committee. In addition, he is chair of the Ethics Working Group of the HIV Prevention Trials Network and is the ethics officer for the Resuscitation Outcomes Consortium. Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, Association of American Physicians, and the Institute of Medicine. He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center.


testacropGiuseppe Testa, MD, PhD, MA

Professor of Molecular Biology at the University of Milan
Director, Laboratory of Stem Cell Epigenetics at the European Institute of Oncology

Giuseppe Testa heads the Laboratory of Stem Cell Epigenetics at the European Institute of Oncology in Milan, where he also co-founded the interdisciplinary PhD program on Life Sciences, Bioethics and Society (Foundations of the Life Sciences and Their Ethical Consequences, Folatec). His STS and bioethics scholarship focuses on the relationship between the life sciences and the evolution of modern democracies. His scientific and bioethics/STS work has appeared in leading peer-reviewed journals. He is the author, with Helga Nowotny, of Naked Genes: Reinventing the Human in the Molecular Age. He holds an MD, a PhD in Molecular Biology and an MA in Bioethics and Law and has been fellow in the Program on Science, Technology and Society at the Harvard Kennedy School within the Branco Weiss Society-in-Science program.


tizzardJuliet TIZZARD, MA

Director of Strategy and Corporate Affairs, Human Fertilisation and Embryology Authority

Juliet has worked in and around IVF for nearly 20 years, starting her career in a small charity and working in the British Medical Association ethics department, before becoming Head of Policy at the HFEA in 2009. During her time at the HFEA, Juliet has overseen large policy reviews and public consultations, such as mitochondrial donation and compensation for egg and sperm donors. She has also been responsible for public campaigns such as One at a Time, a collaborative initiative to reduce the multiple births rate in IVF. Juliet believes that donors, patients and their families should have access to safe, high quality care provided in a strong ethical framework.


wangHaoyi WANG, PhD

Professor at the State Key Laboratory of Stem cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Distinguished Visiting Professor, The Jackson Laboratory

Dr. Haoyi Wang joined the JAX faculty in February 2014, and is a Professor at the Institute of Zoology, Chinese Academy of Sciences, in Beijing. Dr. Wang focuses on developing novel technologies to achieve more efficient and specific genome and epigenome editing. Dr. Wang has an interdisciplinary training in genetics, molecular biology, and stem cell biology and has worked on the development of a variety of genome engineering technologies, including a transposon-based “Calling Card” method for determining the genome-wide binding locations of transcription factors, TALEN-mediated genome editing in human pluripotent stem cells and mice, CRISPR-mediated multiplexed genome editing in mice, and CRISPR-mediated gene activation in human cells.



woodgatePaul WOODGATE

Society & Ethics Research Funding Adviser, Humanities and Social Science, Wellcome Trust

Paul Woodgate is employed by the Wellcome Trust. He advises on its social science and ethics research funding stream. This includes encouraging and supporting high quality grant proposals as well as inputting into the programme’s policies and strategic direction. Paul previously worked for the British Medical Association.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s